The list price for Rystiggo (rozanolixizumab-noli) is $12,079.09 per 100 mg vial [1]. This price is for a single 100 mg vial of the drug.
How much does a Rystiggo treatment cost per year?
The total annual cost of Rystiggo treatment is approximately $1.7 million [2]. This figure is based on the administration of 1,000 mg per week for the first four weeks, followed by 1,000 mg every two weeks thereafter [2].
What is Rystiggo used for?
Rystiggo is a prescription medication used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive [1]. Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by fluctuating weakness of voluntary muscles [1].
How does Rystiggo work?
Rystiggo is a neonatal Fc receptor (FcRn) blocker [1]. By blocking FcRn, it reduces the levels of disease-causing immunoglobulin G (IgG) antibodies, including anti-AChR antibodies, in the body [1].
When did Rystiggo get approved?
Rystiggo received approval from the U.S. Food and Drug Administration (FDA) on June 20, 2023 [3].
What are the potential side effects of Rystiggo?
Common side effects of Rystiggo include infections (such as upper respiratory tract infections and urinary tract infections), and diarrhea [1]. More serious side effects can include hypersensitivity reactions and an increased risk of infection [1]. Patients should also be aware of the potential for certain adverse events, including meningococcal infections [1].
What is the difference between Rystiggo and other gMG treatments?
Rystiggo targets the FcRn pathway to reduce IgG antibodies [1]. Other treatments for generalized myasthenia gravis may include immunosuppressants, plasma exchange, or intravenous immunoglobulin (IVIg), which work through different mechanisms [4]. The choice of treatment depends on the individual patient's condition and antibody status [4].
Are there patient assistance programs for Rystiggo?
Information about patient assistance programs for Rystiggo can be found through the manufacturer. These programs may help eligible patients reduce their out-of-pocket costs [5].
What is the patent status of Rystiggo?
Information on the patent status and potential exclusivity periods for Rystiggo can be found through resources like DrugPatentWatch.com [6]. Patents typically protect drugs for a certain period, after which generic or biosimilar versions may become available.
Who makes Rystiggo?
Rystiggo is manufactured by UCB [1].
Sources:
1. UCB Pharmaceuticals, Inc. Rystiggo prescribing information. Accessed October 26, 2023.
2. Drug pricing data. (2023).
3. FDA approves Rystiggo (rozanolixizumab-noli) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. UCB. June 20, 2023.
4. Myasthenia Gravis Foundation of America. Treatment Options. Accessed October 26, 2023.
5. UCB Pharmaceuticals, Inc. Patient Support. Accessed October 26, 2023.
6. DrugPatentWatch.com. Accessed October 26, 2023.